GlassScriptPhysician profile
Yasir Shareef
NPI 1336178235
$3,847.04
in general payments reported to CMS, 2019-2025
34 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $447 · 2021: $890 · 2022: $1,085 · 2023: $620 · 2024: $81.99 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $675.48 | 2019-2023 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $371.01 | 2021-2023 | Botox, Ubrelvy |
| Allergan, INC. | $347.17 | 2019-2022 | |
| Sk Life Science, INC. | $331.18 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $328.75 | 2019-2024 | |
| Livanova USA, INC. | $212.22 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ge Healthcare | $180.20 | 2024-2025 | |
| Lilly USA, LLC | $162.82 | 2020-2023 | Emgality, Reyvow, Amyvid |
| Amgen INC. | $133.18 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $124.88 | 2022-2023 | Ajovy |
| Biogen, INC. | $105.93 | 2019 | |
| Eisai INC. | $87.23 | 2019-2022 | |
| Emd Serono, INC. | $82.72 | 2025 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $78.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $67.60 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $66.92 | 2022-2023 | Wakix |
| Corium, LLC | $61.44 | 2022-2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $52.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.76 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $35.15 | 2022-2023 | Amvuttra |
| Lundbeck LLC | $32.49 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $31.79 | 2020-2022 | |
| Banner Life Sciences, LLC | $30.89 | 2021-2022 | |
| Argenx US, INC. | $29.82 | 2023 | Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $29.26 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $28.64 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $17.18 | 2023 | Aptiom |
| Pfizer INC. | $17.07 | 2023 | |
| Arbor Pharmaceuticals, INC. | $13.59 | 2022 | |
| Neurelis, INC. | $13.29 | 2020 | |
| Celgene Corporation | $12.79 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.70 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasir Shareef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.